As flowers bloom and temperatures climb, spring brings in allergy season for many. When sneezing, itchy eyes or sinus ...

Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in ...

Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in ...

Notably, patients with nasal polyps experienced improvements in both symptoms and polyp size after ... LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing ...

Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma ...

The US regulator has asked for additional clinical data ... for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi/Regeneron's IL-4 and IL-13 ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

After the first dose, it's given every two weeks under a doctor's guidance, either in a clinic or at home after ... chronic sinus inflammation with nasal polyps, eosinophilic food pipe ...